Trials Today

Comparing UroLift Experience Against Rezūm

Purpose

C.L.E.A.R. Study is poised to compare the patient experience post procedure, including catheterization needs as well as retreatment and BPH medication rates following treatment with either the UroLift® System or Rezūm™ System through 12 months.

Condition

Benign Prostatic Hyperplasia

Eligibility

Eligible Ages: Over 50 Years
Eligible Genders: Male
Accepts Healthy Volunteers: Yes

Inclusion Criteria

Male gender 2. Age ≥ 50 years 3. Diagnosis of symptomatic BPH 4. Prostate volume 30cm3 ≤ 80cm3 5. Willing to sign study informed consent form

Exclusion Criteria

Current urinary tract infection 2. Current catheter dependent urinary retention or PVR >= 500 mL 3. Urethra conditions that may prevent insertion of delivery system into bladder 4. Previous BPH surgical procedure 5. Urinary incontinence presumed due to incompetent sphincter 6. Current gross hematuria 7. Patients with a urinary sphincter implant 8. Patients who have a penile prosthesis 9. Currently enrolled in any other investigational clinical research trial that has not completed the primary endpoint

Study Design

Phase: N/A
Study Type: Interventional
Allocation: Randomized
Intervention Model: Parallel Assignment
Primary Purpose: Treatment
Masking: None (Open Label)

Arm Groups

Arm	Description	Assigned Intervention
Experimental UroLift	Patient randomized to the UroLift arm will receive the FDA-approved UroLift procedure.	Device: UroLift The UroLift System is indicated for the treatment of symptoms due to urinary outflow obstruction secondary to benign prostatic hyperplasia (BPH). During the procedure, an implant is delivered into the prostatic lobe obstructing the urethra and restricting urine flow. The distal end of the device is used to compress the lobe then the implant is delivered to retain the lobe in position, thereby increasing the urethral opening and reducing the fluid obstruction through the prostatic urethra.
Experimental Rezūm	Patient randomized to the Rezūm arm will receive the FDA-approved Rezūm procedure.	Device: Rezum The Rezūm™ System is intended to relieve symptoms, obstructions, and reduce prostate tissue associated with BPH. The Rezūm System is manufactured by Boston Scientific and consists of a radiofrequency (RF) generator and a single-use transurethral delivery device. The Rezūm System utilizes radiofrequency current to generate "wet" thermal energy in the form of water vapor, which is then injected into the transition zone and/or median lobe of the prostate tissue in controlled 9-second doses. The vapor that is injected into the prostate tissue rapidly disperses through the interstitial space between the tissue cells. As the vapor cools, it condenses immediately on contact with tissue and the stored thermal energy is released,reducing the volume tissue adjacent to the urethra.

Recruiting Locations

More Details

NCT ID: NCT04338776
Status: Active, not recruiting
Sponsor: NeoTract, Inc.

Detailed Description

Patients will be randomized to either the UroLift or Rezum arm. Post-procedure, subjects who receive a catheter between post-procedure and prior to discharge, will return to office to complete a voiding assessment. All subjects will be expected to complete questionnaires and assessments, as part of SOC (varies by institution), at day 3, day 7, 2 weeks, 1 month, 3 months and 12 months post-procedure.